| Literature DB >> 31509949 |
Martin Kellert1, Peter Lönnecke2, Bernd Riedl3, Johannes Koebberling4, Evamarie Hey-Hawkins5.
Abstract
The amount of boron accumulated in tumor tissue plays an important role regarding the success of the boron neutron capture therapy (BNCT). In this article, we report a modular system, combining readily available starting materials, like glycine, 1,3,5-triazine and the well-known 9-mercapto-1,7-dicarba-closo-dodecaborane(12), as well as α-d-galactopyranose for increased hydrophilicity, with a novel boron-rich tris-meta-carboranyl thiol.Entities:
Keywords: boron neutron capture therapy; cancer therapy; carborane; modular system; s-triazine
Mesh:
Substances:
Year: 2019 PMID: 31509949 PMCID: PMC6767515 DOI: 10.3390/molecules24183288
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Illustration of the modular system incorporating an α-d-galactopyranosyl moiety (yellow), protected glycine (blue), a tris-cluster derivative of 9-mercapto-1,7-dicarba-closo-dodecaborane(12) (pale red) and cyanuric chloride (green) as core; R = tert-butyl.
Scheme 1Preparation of tert-butyl-N-{4,6-bis[(1,7-dicarba-closo-dodecaboran-9-ylmethyl)1,7-dicarba-closo-dodecaboran-9-ylthio]-1,3,5-triazin-2-yl}-N-(1′,2′:3′,4′-di-O-isopropylidene-6′-deoxy-α-d-galacto-pyranos-6′-yl)glycinate (7). a) I2, AlCl3, CH2Cl2, rt, 2 d, 92% [62,63]; b) paraformaldehyde, n-BuLi, tetrahydrofuran (THF), rt, overnight, 89%; c) Br2, PPh3, benzene, reflux, 46 h, 95% [64,65,66]; d) from 3—Mg, THF, reflux, 2 h; e) from 1—11 mol% CuI, 4 mol% [PdCl2(PPh3)2], THF, reflux, 2 d, 30% [61,62,63,64,67,68]; f) S2Cl2, AlCl3, CH2Cl2, reflux, 4 h, 67% [69]; g) Zn, HClconc., glacial acetic acid (HOAc), ethyl acetate, reflux, 4 h, 81% [69]; h) +8, K2CO3, MeCN, reflux, 2 d, 79%.
Figure 2Comparison between 9-mercapto-1,7-dicarba-closo-dedecaboran(12) (left) and 1,7-bis(1,7-dicarba-closo-dodecaboran-9-ylmethyl)-1,7-dicarba-closo-dodecaboran-9-yl-thiol (6) (right) (altered fragments are drawn in red).
Figure 3Molecular structure of 1,7-bis(1,7-dicarba-closo-dodecaboran-9-ylmethyl)-1,7-dicarba-closo-dodecaborane (4). Hydrogen atoms are omitted for clarity. Thermal ellipsoids are drawn at the 50% probability level. Selected bond lengths [pm] and bond angles [°]: C1–C3 153.5(2), C3–B20 160.1(3), C2–C6 153.0(2), C6–B30 159.6(3); C1–C3–B20 123.0(2), C2–C6–B30 124.2(2).
Figure 4Mono-oxidized derivative of 1,2-bis[1,7-bis(1,7-dicarba-closo-dodecaboran-9-ylmethyl)-1,7-dicarba-closo-dodecaboran-9-yl]disulfane (5′).
Figure 5Molecular structure of 1,7-bis(1,7-dicarba-closo-dodecaboran-9-ylmethyl)-1,7-dicarba-closo-dodecaboran-9-ylthiol (6). Thermal ellipsoids are drawn at the 50% probability level. Carbon/boron disorder in one of the carborane clusters in a ratio of 0.55(2):0.45(2) (shown) and the central carborane unit (ratio of 0.938(1):0.062(1), not shown) is observed. Hydrogen atoms (other than SH) are omitted for clarity. Selected bond lengths [pm] and bond angles [°]: S1–B7 187.0(4), C1–C7 152.9(3), C7–B20 159.9(4), C2–C8 152.5(4), C8–B30 160.3(4); C1–C7–B20 122.7(2), C2–C8–B30 124.2(2).
Figure 6Comparison of the isotopic pattern of the calculated (top) and measured signal (bottom) of [7 + H]+ [41].
Figure 7Numbering scheme of compound 7.